

Special Issue

COVID-19: Epidemiology and Transmission

Message from the Guest Editors

Vaccination is considered the most promising way to end the COVID-19 pandemic while restoring social activities. A collective global effort has been invested into the vaccination against SARS-CoV-2. As of December 2021, eight vaccines have been approved for use by WHO whilst over 300 vaccine candidates are under (pre-)clinical development. As a result, vaccination campaigns have been carried out in many countries while the coverage varies greatly. While the vaccination has been proven to significantly reduce the development of severe symptoms after infection from the original and certain mutated strain of the virus, the emergence of new mutated strains would potentially disrupt such protection, for example, Omicron. In this Special Issue, all studies and reviews that can shed new light on the mechanisms, storage, efficiency, dosage specification, and side effects of COVID-19 vaccines, or those that can elucidate the vaccination strategies in the context of limited vaccination capacity and the effect of vaccines in the transmission, are all welcome.

Guest Editors

Prof. Dr. Xiaohua Zhou

1. PKU Endowed Chair Professor, Beijing International Center for Mathematical Research, Peking University, Beijing, China
2. Chair, Department of Biostatistics, School of Public Health, Peking University, Beijing, China

Dr. Chong You

Beijing International Center for Mathematical Research, Peking University, Beijing, China

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/107079

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).